Your cart
Your cart is empty
Continue shopping
Pharmacor
Gilmat (Imatinib)
Sale price
$79.99
-8%
Regular price
$86.05
Regular price
$79.99
Unit price
per
Low stock
In stock, ready to ship
Product Sold Out
More Information (API / 100mg x 60 Tabs)
Active Ingredients
imatinib mesilate 119.5mg Equivalent: imatinib 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (API / 400mg x 30 Tabs)
Active Ingredients
imatinib mesilate 478mg Equivalent: imatinib 400mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured capsule shaped bevel edged scored film coated tablet debossed with H on one side and 20 on the other side, 2 and 0 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (Sigma / 100mg x 60 Tabs)
Active Ingredients
imatinib mesilate 119.5mg Equivalent: imatinib 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (Sigma / 400mg x 30 Tabs)
Active Ingredients
imatinib mesilate 478mg Equivalent: imatinib 400mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (Symbion / 100mg x 60 Tabs)
Active Ingredients
imatinib mesilate 119.5mg Equivalent: imatinib 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (Symbion / 400mg x 30 Tabs)
Active Ingredients
imatinib mesilate 478mg Equivalent: imatinib 400mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (CH2 / 100mg x 60 Tabs)
Active Ingredients
imatinib mesilate 119.5mg Equivalent: imatinib 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (CH2 / 400mg x 30 Tabs)
Active Ingredients
imatinib mesilate 478mg Equivalent: imatinib 400mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
Tablet Description
White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
Connecting Care, Simplifying Supply.
At Pharmacor, we bridge the gap between healthcare providers and seamless supply solutions, ensuring care is always within reach.
Image
Product Name
Wholesaler
Strength/Pack Size
Product Info
